Acute and chronic neutropenias. What is new?

Palmblad J, Papadaki HA, Eliopoulos G (The Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden and University of Crete Medical School, Heraklion, Greece). Acute and chronic neutropenias. What is new? J Intern Med 2001; 250: 476–491. Recently, some of the mechanisms and consequences in the severe chronic neutropenias (e.g. the neutrophil elastase gene mutations and the risk to progress to myelodysplasia and acute leukaemia) and in drug‐induced agranulocytosis (e.g. the apoptosis‐inducing ability of metabolites of clozapine) have been elucidated, and new aspects of autoimmune and the large granular lymphocyte syndrome were described (e.g. aberrant elaboration of Fas‐ligand causing neutrophil apoptosis). Investigations of the mild to moderate chronic neutropenias have shown the significance of interactions between the myeloid development and the immune network (e.g. relations to immunoglobulin aberrations). Granulocyte‐colony stimulation factor (G‐CSF) is widely used in patients with severe chronic neutropenia, however, its use in other conditions is mostly based on anecdotal evidence. In addition, immune modulating regimens, such as metothrexate, ciclosporine and monoclonal antibodies, are increasingly employed for the autoimmune neutropenias.